Navigation Links
Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City
Date:3/30/2011

BASKING RIDGE, N.J., March 30, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Needham & Company's 10th Annual Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, April 6, 2011 at 11:20 a.m. EDT.  The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the REG1 phase 2b trial (RADAR) results.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its compleme
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Calif. , May 28, 2015  IRIDEX Corporation (NASDAQ: ... Chief Financial Officer James H. Mackaness is scheduled ... 3, 2015, at 9:00 am PT in Los ... the presentation may be accessed on the Event Calendar of ...  A replay of the webcast will be available shortly after ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of the "United States ... report to their offering.      (Logo: ... adhesives in the United States ... 2020 Medical device manufacturers across ...
(Date:5/28/2015)... , May 28, 2015 The Parenteral ... be a supporting organization of the Johnson & ... in 2016. Johnson & Johnson (J&J) ... high-profile superbug infections in endoscopes. J&J ran 8 ... between 1976 and 2003 on advances in sterilization ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3PDA Announces Support for the Johnson & Johnson Kilmer Conference 2
... 29, 2007 /PRNewswire-USNewswire/ -- Evidence is,accumulating that depression ... 2007 issue of Harvard Women's Health Watch. A,recent ... who regularly took,antidepressants called selective serotonin reuptake inhibitors,(SSRIs) ... not using such,medications. Other research points to depression ...
... CELSION CORPORATION,(AMEX:CLN) today announced the completion of ... to treat non-resectable liver,cancer. The study which ... Agreement (CRADA) was performed at the National,Cancer ... Health, under,the leadership of Dr. Steven K. ...
Cached Medicine Technology:Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch 2Celsion Completes Enrollment in Phase I Liver Cancer Study 2Celsion Completes Enrollment in Phase I Liver Cancer Study 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... to educate readers on the importance of proper sun ... within USA Today, with a circulation of approximately 250,000 ... digital component is distributed nationally, through a vast social ... sites and partner outlets. To explore the digital version ...
(Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
(Date:5/29/2015)... The Croatia Cosmetic Dentistry Center - ... on what modern dentistry options are available today. The ... to revolutionize the perception of a dental practice — ... Spa. , The top dental provider is partnered ... tourism agencies and led by world-renowned experts, Dr. ...
(Date:5/29/2015)... MN (PRWEB) May 29, 2015 As ... Patio and Metro series outdoor saunas have increased in ... landscaping projects, and work at summer cottages. While ... piqued interest in summer projects a few weeks earlier ... suburban communities with smaller lot sizes tend to prefer ...
(Date:5/29/2015)... Michigan (PRWEB) May 29, 2015 Vulvodynia ... and can cause significant physical, sexual, and psychological distress. ... altering disorder of Vulvodynia. The actual diagnosis is often ... in Endometriosis, they realize that this problem can be ... experiencing any of these symptoms, they need to schedule ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... ... Dentistry (AGD) announces that Aria Irvani, DDS, of Orange county CA, received the Mastership ... dental education.,To accomplish this, Dr. Irvani completed 1,100 hours of approved continuing dental education ... techniques. , ...
... CRUZ, CA--New connections begin to form between brain cells almost ... study published this week in Nature . Led by ... involved detailed observations of the rewiring processes that take place ... mice as they were trained to reach through a slot ...
... something leads to more self-defensive finger pointing, study finds , ... a contagious one, a new study reports, even when the ... someone blame someone else for a problem, even if it,s ... blaming others, too. , "When we see others protecting ...
... the sleep disorder boosts urine production, experts say , ... during the night to urinate shouldn,t automatically blame a urological ... cause. , A new study suggests that nighttime urination, or ... obstructive sleep apnea, a disorder in which soft tissue in ...
... ... costs open the door for viable affordable alternative care. Affordable Acupuncture Scottsdale answers the ... (PRWEB) ... year (2009) and has been met with enthusiasm and gratitude. Its increasing popularity and ...
... 28 Get ready for advanced visualization to become ... introduces syngo. via(1) at the ... America (RSNA) from November 29 to December 3 at McCormick Place (Booth ... syngo. via , Siemens, new imaging software ...
Cached Medicine News:Health News:Orange County Dentist Honored by The Academy of General Dentistry 2Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:When Accusations Start to Fly, They Multiply 2Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5
... Drug Monitoring Market in 1981 with the ... today, this system uses technology known as ... drug concentration in a patient. Therapeutic Drugs, ... often exhibit a narrow therapeutic range requiring ...
Architect i2000SR provides high productivity. Seamless integration optimize performance....
... ADVIA Centaur delivers a new ... provides the flexibility to integrate ... now and in the future. ... comprehensive disease-focused menu of immunoassays ...
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
Medicine Products: